DE60131001D1 - Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten - Google Patents

Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten

Info

Publication number
DE60131001D1
DE60131001D1 DE60131001T DE60131001T DE60131001D1 DE 60131001 D1 DE60131001 D1 DE 60131001D1 DE 60131001 T DE60131001 T DE 60131001T DE 60131001 T DE60131001 T DE 60131001T DE 60131001 D1 DE60131001 D1 DE 60131001D1
Authority
DE
Germany
Prior art keywords
oxazolylarylpropionic
acid derivatives
ppar agonists
compounds
solvates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60131001T
Other languages
English (en)
Other versions
DE60131001T2 (de
Inventor
Robert J Ardecky
Dawn Alisa Brooks
Alexander Glenn Godfrey
Sarah Beth Jones
Nathan Bryan Mantlo
James Ray Mccarthy
Pierre-Yves Michellys
Christopher John Rito
John S Tyhonas
Leonard Larry Winneroski
Yanping Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand Pharmaceuticals Inc
Eli Lilly and Co
Original Assignee
Ligand Pharmaceuticals Inc
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharmaceuticals Inc, Eli Lilly and Co filed Critical Ligand Pharmaceuticals Inc
Application granted granted Critical
Publication of DE60131001D1 publication Critical patent/DE60131001D1/de
Publication of DE60131001T2 publication Critical patent/DE60131001T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60131001T 2000-08-23 2001-08-23 Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten Expired - Lifetime DE60131001T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22745600P 2000-08-23 2000-08-23
US227456P 2000-08-23
PCT/US2001/022617 WO2002016332A1 (en) 2000-08-23 2001-08-23 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

Publications (2)

Publication Number Publication Date
DE60131001D1 true DE60131001D1 (de) 2007-11-29
DE60131001T2 DE60131001T2 (de) 2008-07-17

Family

ID=22853183

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60131001T Expired - Lifetime DE60131001T2 (de) 2000-08-23 2001-08-23 Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten

Country Status (10)

Country Link
US (1) US7176224B2 (de)
EP (1) EP1313717B1 (de)
JP (1) JP2004506722A (de)
AT (1) ATE375985T1 (de)
AU (1) AU2001284660A1 (de)
CA (1) CA2418134A1 (de)
DE (1) DE60131001T2 (de)
ES (1) ES2295200T3 (de)
MX (1) MXPA03001610A (de)
WO (1) WO2002016332A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982278B2 (en) 2000-08-23 2006-01-03 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
WO2002016331A1 (en) * 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
CZ20033309A3 (cs) * 2001-06-07 2004-05-12 Eliálillyáandácompany Modulátory receptorů aktivovaných peroxizomálními proliferátory }PPARB
EA200400011A1 (ru) * 2001-06-07 2004-06-24 Эли Лилли Энд Компани Модуляторы рецепторов, активируемых пролифераторами пероксисом (prar)
EP1445258B1 (de) * 2001-10-12 2009-06-24 Nippon Chemiphar Co., Ltd. Aktivator des peroxisomproliferator-aktivierten rezeptors delta
US20050080115A1 (en) * 2002-10-28 2005-04-14 Lone Jeppesen Novel compounds, their preparation and use
DE60317365T2 (de) * 2002-11-08 2008-08-21 F. Hoffmann-La Roche Ag Substituierte 4-alkoxyoxazol derivate als ppar agonisten
US7192970B2 (en) * 2002-11-26 2007-03-20 Chipscreen Biosciences, Ltd. Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity
AU2004212887A1 (en) 2003-02-14 2004-09-02 Eli Lilly And Company Sulfonamide derivatives as PPAR modulators
DE102004060227B3 (de) * 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
JPWO2007013694A1 (ja) * 2005-07-29 2009-02-12 武田薬品工業株式会社 フェノキシアルカン酸化合物
RU2536409C2 (ru) 2009-08-05 2014-12-20 Дайити Санкио Компани, Лимитед Амидное производное
AU2011314712B2 (en) * 2010-10-14 2016-05-26 Daiichi Sankyo Company,Limited Acylbenzene derivative

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5232945A (en) * 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
JP2002503202A (ja) 1996-02-02 2002-01-29 メルク エンド カンパニー インコーポレーテッド 抗糖尿病薬
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
CA2263721A1 (en) * 1996-08-19 1998-02-26 Satoshi Ohrui Propionic acid derivatives and applications thereof
ATE451346T1 (de) 1998-03-10 2009-12-15 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
DE60005973T2 (de) * 1999-08-27 2004-05-13 Eli Lilly And Co., Indianapolis Biaryl-oxa(thia)zolderivate und ihre verwendung als ppars modulatoren
JP4316787B2 (ja) 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
US6982278B2 (en) 2000-08-23 2006-01-03 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
WO2002016331A1 (en) * 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

Also Published As

Publication number Publication date
WO2002016332A1 (en) 2002-02-28
US7176224B2 (en) 2007-02-13
US20040138277A1 (en) 2004-07-15
DE60131001T2 (de) 2008-07-17
ATE375985T1 (de) 2007-11-15
MXPA03001610A (es) 2003-09-10
EP1313717B1 (de) 2007-10-17
EP1313717A1 (de) 2003-05-28
JP2004506722A (ja) 2004-03-04
ES2295200T3 (es) 2008-04-16
AU2001284660A1 (en) 2002-03-04
CA2418134A1 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
ATE496620T1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
ATE297910T1 (de) Retinoid x rezeptormodulatoren
DK1177187T3 (da) Diarylsyrederivater som PPAR-receptorligander
MXPA03004549A (es) Derivados de 3-arilindola y su uso como agonistas del receptor cb2.
ATE302775T1 (de) Carbolinderivate
ATE245644T1 (de) 1,3-dihydro-2h-indol-2-on derivate und deren verwendung als liganden der arginin-vasopressin rezeptoren v1b oder v1b und v1a
YU80902A (sh) Novi indolin-2-on derivati, njihovo dobijanje i farmaceuski oblici koji ih sadrže
DE60131001D1 (de) Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten
ATE346067T1 (de) Carbolinderivate
MXPA05012247A (es) Derivados de bencimidazol nuevos.
ATE300541T1 (de) Pyrazolopyridinderivate
ATE374190T1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
DE602005009512D1 (de) 3-((hetero)arylsulfonyl)-8-ä(aminoalkyl)oxyüchinoline als antagonisten des 5-ht6-rezeptors zur behandlung von erkrankungen des zns
ATE417838T1 (de) Arylsulfonyl-derivate mit 5-ht 6-rezeptor- affinität
ATE453389T1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
DE60208694D1 (de) Piperidinylmorpholinylderivate als modulatoren der aktivität des chemokinrezeptors
ATE447575T1 (de) Selektive spirocyclische glucocorticoid-rezeptor- modulatoren
NO963331L (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
ATE254122T1 (de) Indolderivate als 5-ht1b und 5-ht1d agonisten
SE0402284D0 (sv) New heterocyclic amides
ATE274515T1 (de) Pyrazolopyridinderivate
ATE465151T1 (de) 4-aryloxy-chinolin-derivate als 5-ht6-modulatoren
ATE337320T1 (de) Indolderivate als pde5-inhibitoren
DE60222465D1 (de) Pyrazolopyridin-derivate als antiherpesmittel
ATE406363T1 (de) Methylindole und methylpyrrolopyridine als alpha- 1-adrenerge agonisten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition